(Q34108728)

31 July 2017

title

Antisense gets a grip on miR-122 in chimpanzees (English)

1 reference

31 July 2017

2

Charles M Rice

1 reference

31 July 2017

Andrea D Branch

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

Science Translational Medicine

31 July 2017

published in

1 reference

31 July 2017

volume

2

1 reference

31 July 2017

issue

13

1 reference

31 July 2017

page(s)

13ps1

1 reference

The quasispecies nature and biological implications of the hepatitis C virus

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000605

Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000605

microRNA-122 stimulates translation of hepatitis C virus RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000605

Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000605

Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000605

Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000605

LNA-mediated microRNA silencing in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000605

Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000605

Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000605

Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000605

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000605

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000605

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000605

Public health impact of antiviral therapy for hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000605

MicroRNA expression, survival, and response to interferon in liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000605

Optimal therapy in genotype 1 patients

21 January 2018

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCITRANSLMED.3000605

Protease and polymerase inhibitors for the treatment of hepatitis C.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCITRANSLMED.3000605

Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922)

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCITRANSLMED.3000605

Identifiers

DOI

10.1126/SCITRANSLMED.3000605

1 reference

31 July 2017

1 reference